Company PharmaEssentia Corporation

Equities

6446

TW0006446008

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Ratings for PharmaEssentia Corporation

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

End-of-day quote Taiwan S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
285.5 ^TWD	-1.04%		0.00%	-17.49%

Apr. 26	PharmaEssentia Corp. Submits Phase III Clinical Study Protocol of P1101 for Pre-fibrotic/ Early PMF or OvertPMF at Low to Intermediate-1 Risk to China NMPA	CI
Apr. 24	PharmaEssentia Corp. Announces Submission of Marketing Authorization Application of BESREMi (Ropeginterferon alfa-2B) for PV in Colombia	CI

PharmaEssentia Corp is a Taiwan-based company mainly engaged in the research, development, production and sale of new drugs. The Company is engaged in the research and development of new drugs, which are used for treatment of hematology, such as meloproliferative neoplasms (MPN), neutropenia, anemia; infectious disease, such as hepatitis C and hepatitis B; dermatology, such as psoriasis, and neurology, such as multiple sclerosis, among others. The Companyâs products include KX01, P1101, Polycythemia Vera (PV), PEG-GCSF, PEG-EPO and others. The Company distributes its products within domestic market and to overseas markets.

Number of employees: 131

TWD in Million	2021	Weight	2022	Weight	Delta
Self-made and Purchased Drugs 99.9 %	633	96.4 %	2,879	99.9 %	+354.77%
Labor 0.1 %	23	3.6 %	3	0.1 %	-88.70%

TWD in Million	2021	Weight	2022	Weight	Delta
Americas 67.0 %	72	11.0 %	1,931	67.0 %	+2,568.61%
Europe 21.3 %	205	31.3 %	614	21.3 %	+199.08%
Taiwan 10.6 %	343	52.2 %	307	10.6 %	-10.61%
Asia (excluding Taiwan) 1.1 %	36	5.5 %	30	1.1 %	-15.65%

Managers	Title	Age	Since
Kuo Chung Lin CEO	Chief Executive Officer	-	02-12-31
Hsueh Ling Chang DFI	Director of Finance/CFO	-	15-10-13
Lih-Ling Lin CTO	Chief Tech/Sci/R&D Officer	-	22-07-31
Joe K. Tseng CTO	Chief Tech/Sci/R&D Officer	-	-
Cheng Ku Huang BRD	Director/Board Member	-	06-01-15

Members of the board	Title	Age	Since
Patrick Yang BRD	Director/Board Member	75	14-02-28
Tien Chang BRD	Director/Board Member	-	06-06-29
Ching Liu Chan CHM	Chairman	-	03-08-31
Cheng Ku Huang BRD	Director/Board Member	-	06-01-15
Chao Ho Chen BRD	Director/Board Member	-	09-06-29
Pen Yuan Chen BRD	Director/Board Member	-	06-06-29
Kuo Jung Cheng BRD	Director/Board Member	-	06-06-29
Shih Ying Hsu BRD	Director/Board Member	-	12-09-23
Chin Te Chang BRD	Director/Board Member	-	14-03-26
Jung Chih Yu BRD	Director/Board Member	-	06-06-29

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	340,810,391	253,215,391 ( 74.30 %)	8,905,000 ( 2.613 %)	74.30 %

Name	Equities	%	Valuation
National Development Fund of The Executive Yuan 6.475 %	22,066,296	6.475 %	222 M NT$
Government of Taiwan 2.836 %	9,666,000	2.836 %	97 M NT$
Eon Capital Group Ltd. 1.822 %	6,210,022	1.822 %	62 M NT$
Kuo Chung Lin 1.192 %	4,063,964	1.192 %	41 M NT$
Ching Liu Chan 0.9340 %	3,183,046	0.9340 %	32 M NT$
Pen Yuan Chen 0.6376 %	2,173,155	0.6376 %	22 M NT$
Cheng Ku Huang 0.5018 %	1,710,073	0.5018 %	17 M NT$
Shen Yi Li 0.2421 %	825,242	0.2421 %	8 M NT$
State Street Global Advisors Ltd. 0.1620 %	552,242	0.1620 %	6 M NT$
Sjunde AP-fonden 0.1488 %	507,000	0.1488 %	5 M NT$

PharmaEssentia Corp.

13/F, No. 3 Yuanqu Street Nankang District

115, Taipei

+886 2 2655 7688

http://www.pharmaessentia.com

address PharmaEssentia Corporation(6446)

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

285.5 TWD

Average target price

417.2 TWD

Spread / Average Target

+46.15%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
PHARMAESSENTIA CORPORATION	-17.49%	2.9B
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.05%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-8.28%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs